trending Market Intelligence /marketintelligence/en/news-insights/trending/s5YdSM7iQCIzjr-2Js391A2 content esgSubNav
In This List

Pierre Fabre skin cancer drug combo recommended by UK price watchdog


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Pierre Fabre skin cancer drug combo recommended by UK price watchdog

The U.K. National Institute of Health and Care Excellence recommended a combination of Pierre Fabre SA's drugs Braftovi and Mektovi for a type of skin cancer.

The pricing watchdog gave the nod to the combination for treating adults with BRAF V600 mutation-positive melanoma whose cancers have spread across the body and cannot be removed through surgery.

The BRAF V600 mutation is found in some cancers and may increase the growth and spread of cancer cells, while testing for the mutation can help plan treatment for the disease.

NICE also said Braftovi and Mektovi appeared to be as effective as Novartis AG's Tafinlar and Mekinist when compared indirectly in treating the disease. Tafinlar, or trametinib, and Mekinist, or dabrafenib, were recommended by the U.K. regulator in September 2018.

The combination is approved by the U.S. Food and Drug Administration and the European Commission.

Array BioPharma Inc. has the exclusive rights to market Braftovi and Mektovi in U.S. and Canada and has granted Ono Pharmaceutical Co. Ltd. the permission to commercialize both products in Japan and South Korea; Medison in Israel; and Pierre Fabre in all other regions, including Europe, Latin America and Asia, excluding Japan and South Korea.